Fig. 7: TGFβ-blockade augments the efficacy of PD1 immunotherapy.
a Study schematic of TGFβ/PD1 co-blockade in 4T1 tumor bearing mice. b Individual 4T1 tumor volumes for animals treated as in a were determined by measurement with calipers. Each line represents a mouse. n = 15 mice per group. Data are representative of four independent experiments. c 4T1 tumor volumes measured at endpoint, each dot represents a mouse. Mean is depicted. n = 15 mice per group. Data are representative of four independent experiments. p-values were calculated using Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparisons test, and individual values are as follows: hIgG2 + mIgG1 vs αTGFβ + mIgG1, p = 0.0883; hIgG2 + mIgG1 vs hIgG2 + αPD1, p = 0.9768; hIgG2 + mIgG1 vs αTGFβ + αPD1, ****p < 0.0001; αTGFβ + mIgG1 vs αTGFβ + αPD1, *p = 0.0155; hIgG2 + αPD1 vs αTGFβ + αPD1, ****p < 0.0001. d t-SNE plots of CAF subsets separated by treatment group. n = 4 mice per group from two independent experiments. e Study schematic of TGFβ/PD1 co-blockade in MC38 tumor bearing mice. f Individual MC38 tumor volumes for animals treated as in e were determined by measurement with calipers. Each line represents a mouse. g Mice treated as in e were removed from study when tumors reached 900 mm3, and the fraction of animals remaining on study was depicted using a Kaplan-Meier curve. One representative of 4 experiments is shown in f and g, n = 15 mice per group per experiment.
